Sore Throat News and Research

RSS

Allergy sufferers can save out-of-pocket costs by visiting urgent care and retail health clinics instead of ER

In this economy, allergy sufferers are looking for relief from more than sneezing, runny noses, and itchy eyes. And, according to a recent study, they can find relief for both their symptoms and their wallets, saving anywhere from $50 to $400 in out-of-pocket costs per visit if they skip the emergency room and head to urgent care and retail health clinics when they are unable to see their primary physician.

20 May 2010

Prestige Brands Holdings fourth fiscal quarter revenues up 4% to $71.4 million

Prestige Brands Holdings, Inc. today reported results for the fourth fiscal quarter and fiscal year ended March 31, 2010.

13 May 2010

Robotic surgery keeps features intact in head, neck cancer removal procedures

Surgeons who perform procedures to remove head and neck cancers often work for six to eight hours on what is typically major, invasive surgery, which many times comes with facial disfigurement and debilitating side effects for the patient.

13 May 2010

Urgent care and retail health clinics can reduce treatment costs for allergy sufferers

10 May 2010

Labopharm, Gruppo Angelini sign agreement to commercialize OLEPTRO in the U.S.

Labopharm Inc. and Gruppo Angelini today announced they have entered into an agreement to establish a joint venture in the United States for the commercialization of OLEPTRO, a novel once-daily formulation of the antidepressant trazodone approved by the U.S. Food and Drug Administration on February 3, 2010.

29 Apr 2010

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Takeda Pharmaceutical Company Limited announced today that Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., have completed settlement agreements with six out of eight defendants in patent infringement litigation brought against these parties in response to their Abbreviated New Drug Applications for generic ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl). Takeda recently concluded litigation with the sixth settling defendant.

28 Apr 2010

Hospitals use surgical robot for head and neck tumors

On Dec. 16, the U.S. Food and Drug Administration cleared the da Vinci Surgical System for benign and malignant tumors in such locations as the tongue, tonsils, mouth and voice box.

24 Apr 2010

Merck to market and distribute MBL's Td vaccine in the U.S.

MassBiologics of the University of Massachusetts Medical School and Merck & Co., Inc. announced today that they have entered into an agreement that provides Merck with exclusive rights to market and distribute MBL's tetanus and diphtheria toxoids adsorbed (Td) vaccine in the United States, with the exception of Massachusetts, where MBL will continue distributing the vaccine.

21 Apr 2010

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

16 Apr 2010

Loyola University Medical Center to offer free screenings for oral, head and neck cancer

Oral, head and neck cancers — most of which are preventable — account for approximately 3 percent of all cancer cases in the United States, according to the American Cancer Society. In 2009, more than 35,000 Americans were diagnosed with these cancers and 7,600 died.

8 Apr 2010

Prestige Brands provides update on 9 ¼% Senior Subordinated Notes due 2012 tender offer

Prestige Brands Holdings, Inc. previously announced that, on March 10, 2010, its wholly-owned subsidiary Prestige Brands, Inc. commenced a cash tender offer for any and all of its 9 ¼% Senior Subordinated Notes due 2012, of which $126 million aggregate principal amount were outstanding at that time.

7 Apr 2010

Detroit cancer center to conduct free oral, head and neck cancer screenings

On Friday, April 16, from 2 - 5 p.m., the Barbara Ann Karmanos Cancer Center in Detroit will be conducting free oral, head and neck cancer screenings in conjunction with National Oral Head and Neck Cancer Awareness Week (April 12 – 18.) Some of the symptoms of oral cancer go unnoticed. A simple 10-minute screening exam can determine if there are problems and can help diagnose this disease in its early stage.

3 Apr 2010

Passengers on Brisbane train may have been exposed to measles

A NSW man who was diagnosed with measles travelled in a train from the Brisbane International Airport to South Brisbane about 8am on Saturday.

2 Apr 2010

Research could pave way for new generation of painkillers

An international group of scientists led by Dr Nikita Gamper of the University's Faculty of Biological Sciences has discovered how two proteins play a key role in the way we feel pain, offering new targets on which drug development can be focused.

25 Mar 2010

Tips on healthy eating post-surgery

Good nutrition, with adequate calories and protein, is important to healing and recovery after major surgery. But the stress of surgery and follow-up care can depress the appetite, alter the taste of food and make it difficult to eat and digest food, sometimes for weeks or months.

20 Mar 2010

Renhuang Pharmaceuticals' net income for first-quarter of 2010 increases 17.8%

Renhuang Pharmaceuticals, Inc., a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines, today announced its financial results for the first quarter ended January 31, 2010.

17 Mar 2010

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Data evaluating the efficacy and safety of STELARA™ (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Fla., from March 5-9, 2010.

5 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

At the 17th Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented new data across its broad range of investigational and current medicines for the treatment of HIV/AIDS. Highlighted data at the conference included an oral presentation on the investigational integrase inhibitor, S/GSK1349572, as well as data presentations on SELZENTRY® (maraviroc) and EPZICOM® (abacavir/lamivudine).

24 Feb 2010

Prestige Brands Holdings announces results for third fiscal quarter ended December 31, 2009

Prestige Brands Holdings, Inc. today announced results for the third fiscal quarter and nine months ending December 31, 2009.

5 Feb 2010